News Center

The latest news, insights and resources from Prothena

Featured Articles

The Longest Day: Shining a Light on LuPita’s Story

  Today marks The Longest Day. It’s the summer solstice and the day with the most sunlight all year long. Also today, we stand with the Alzheimer’s community to fight the darkness of Alzheimer’s disease and all other dementias. There has been remarkable progress in the treatment of Alzheimer’s disease in the past few years, […]

A novel mechanism of action to address unmet needs in AL amyloidosis

AL amyloidosis, a rare, progressive and often fatal disease, occurs when a type of immune cell, called plasma cells, produce high levels of an abnormal protein called light chain that misfolds and clumps together to form aggregated amyloid which the body cannot break down. Clumped together, the amyloid can travel through blood vessels, damaging cells […]

Yvonne Tchrakian, Corporate Secretary and Legal Counsel at Prothena, shares her perspective on supporting women, including mothers, in the workplace

Earlier this year we heard from Donna-Lee Destouche who shared advice on encouraging the next generation of female leaders in STEM. In her interview, she notes, “if we have some support to be ambitious in our career, and perhaps not lose a step because you’ve decided you wanted to start a family, we may have […]

Understanding Proteins — their role in life, and in some of the most challenging diseases we face today

Proteins are essential for life. Every cell in our body makes protein every day. And for those proteins to work correctly, they need to fold in a certain three-dimensional shape and space. Systems in our cells recognize misshapen proteins and try to fix them. If they can’t help fold them into the correct shape, the […]

On advice: Linda shares wisdom for other AL amyloidosis patients

March is Amyloidosis Awareness Month, and at Prothena we believe it’s important to shine light on firsthand perspectives from people directly impacted by the disease. In this video, Linda offers advice to those affected by AL amyloidosis. Whether advice for others impacted by the disease, the journey to diagnosis, or working together with a care […]

Amyloidosis Foundation President Mary O’Donnell answers questions about the organization’s work in amyloidosis

AL amyloidosis is a rare, progressive and life-threatening disease that leads to the production and aggregation of misfolded toxic light chain proteins. These aggregates cause problems in the body’s circulation, depositing in the heart and kidney, leading to damage and organ failure. Patients often present with a wide range of general symptoms that are common […]

Donna-Lee Destouche, Head of Clinical Trial Management at Prothena, shares her perspective on supporting women and girls in science and the importance of Rare Disease Day

February 29, 2024 marks Rare Disease Day, and we’re honored to hear from Donna-Lee about the importance of this day and her personal connection to rare disease. Check out the video below and hear from more Prothenians on why they care about rare here.     Earlier this month, we celebrated International Day of Women […]

Hear from Prothena CEO Gene Kinney on the progress made across the Alzheimer’s disease industry and his outlook for 2024

From selecting appropriate patients for clinical studies, to identifying the right endpoints and biomarkers, 2023 was marked with the very first disease-modifying treatments for Alzheimer’s disease. Looking ahead in 2024, the field is poised to do an even better job of slowing the relentless disease progression of Alzheimer’s disease.   As we gear up for […]

Prothena Participates in the Walk to End Alzheimer’s

Held annually in more than 600 communities nationwide, the Alzheimer’s Association Walk to End Alzheimer’s® is the world’s largest event to raise awareness and funds for Alzheimer’s care, support and research. Last month, Prothenians showed their support by participating in walks across the globe – including Dublin, San Francisco, San Diego, Philadelphia and Boston. As […]

Reflecting on CTAD 2023, and the inspiring progress of Alzheimer’s disease R&D this year

Over 25 Prothenians attended the 16th annual Clinical Trials on Alzheimer’s Disease (CTAD) meeting in October in Boston, Massachusetts. As always, it was inspiring to join experts in the space to discuss the latest advances in Alzheimer’s disease R&D as we work toward a shared goal of delivering better treatments to patients. Throughout the year […]

Ingrid Sprinz, PhD, Senior Medical Director, Hematology, answers questions about Prothena’s work in AL amyloidosis

Today, World Amyloidosis Day, we recognize people living with AL amyloidosis and their caregivers for their unwavering strength. We recently sat down with Ingrid Sprinz, PhD, Senior Medical Director, Hematology, to speak about current needs in the treatment of AL amyloidosis and Prothena’s progress in the space. Check out her perspective below.   Q: What […]

How Linda’s Persistence Played a Role in her AL Amyloidosis Diagnosis

“I want my kidneys biopsied.” In this powerful video, we hear about the journey to diagnosis from Linda, a daughter, mother and wife living with AL amyloidosis. After fifteen symptoms materialized over the course of just two years, Linda knew something wasn’t right. From severe back pain, sudden high blood pressure and uncontrollable vomiting, to […]

#ProthenaProud: Hear from Jun Lee, Associate Director, Clinical Science, as he shares his experience working at Prothena

Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.

Hear from Prothena’s Ria Palarca and Nhu Truong on women’s equality at Prothena

  Tomorrow, August 26, marks Women’s Equality Day, but each day we are proud of the women who work to advance science and truly impact patient lives. We recently had the chance to hear from Ria Palarca and Nhu Truong on the importance of equal opportunity and a supportive workplace. Check out their perspectives below. […]

Prothena’s presence at AAIC 2023 amidst a transformative time in the field of Alzheimer’s disease R&D

The Alzheimer’s disease space continues to buzz with news – advancements in the science and understanding of the disease, availability of new treatment options, and a newfound sense of hope for the Alzheimer’s community. In a recent interview with PharmaVoice, Prothena CEO Gene Kinney shares, “Science is an iterative process, and for a disease as […]

Mike and Donna on Fighting the Same Enemy

In this inspiring video, we hear how Mike’s amyloidosis has affected not only him, but his wife Donna and their marriage, too. In fact, they actually agree the diagnosis has brought them closer. Like many diseases, it is important to remember that amyloidosis changes the lives of more than just the patient. Donna, Mike’s primary […]

The Future of Alzheimer’s Disease Research, an OpEd by Donna Masterman, VP Medical Affairs, Neuroscience Lead, Prothena

Throughout the last year, we’ve seen some of the most significant breakthroughs to date in Alzheimer’s disease research, most notably—solidifying that anti-Aβ is a viable and clinically-sound treatment pathway. This is only the beginning, and we at Prothena are both proud and excited to be a part of developing the next generation of therapies for […]

An open letter from Francisco Lio, Senior Director, Global Program Manager

  Prothena is working to develop new treatments for people facing some of the world’s most devastating diseases, including neurodegenerative diseases like Alzheimer’s and Parkinson’s. It’s a challenging mission that attracts people who are passionate and committed including Francisco Lio, our Senior Director, Global Program Manager, who manages interdisciplinary teams responsible for two promising Alzheimer’s […]

#ProthenaProud: Hear from Kendell Hardy, Senior Director, Human Resources, as she shares her experience working at Prothena

Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.

Suzanne Ostrander, Head of Clinical Operations at Prothena, answers questions about Prothena’s new partnership with Walgreens

  Q: Why is Prothena partnering with Walgreens? A: Our collaboration with Walgreens should accelerate patient identification and increase access and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial, which is evaluating the safety and tolerability of PRX012. PRX012 is a potential best-in-class anti-Aβ antibody under development for the treatment of Alzheimer’s disease […]